In summary, the study showed that oral carnosine supplementation could reduce urinary TGF-β level in T2DM with diabetic nephropathy, but without significant effects on urine albumin, indicating an additional renoprotective effect from conventional therapy. Here, TGFB1 is linked to type 2 diabetes mellitus.